



News Release

Suven to Present at Alzheimer's Association International Conference (AAIC)

HYDERABAD, INDIA (July 25, 2016): Suven is exhibiting and presenting several exciting new results and data presentations from Suven's portfolio of investigational neuroscience **New Chemical Entities (NCEs)** are being presented at **Alzheimer's Association International Conference (AAIC)** being held in Toronto, Canada during July 24th to 28th, 2016.

AAIC is the world's largest conference of its kind, where thousands of international investigators, clinicians, researchers and care providers will gather to share the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.

Alzheimer's disease is one of the scourges of modern day health care. **Alzheimer's is not just a memory loss as everyone thinks but Alzheimer's kills.** Current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing and this is where **Suven is focusing in developing a drug for the treatment of this debilitating disease.**

Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT₆, 5-HT₄, H₃ and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer's disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia.** In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information on Suven, please visit our Web site at <http://www.suven.com>

Safe Harbor Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;